Crestline Management, L.P.
Long book
$46.3M
Q1 2026
Positions
3
Top-10 weight
100%
concentration
Last quarter
+33.9%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsCrestline Management, L.P. is a diversified fundamental manager, specialised in healthcare (96% of the long book), running a $46.3M US long book across 3 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: DENALI THERAPEUTICS INC, SANA BIOTECHNOLOGY INC, 8X8 INC.
Over the last 9 quarters its long book ran on average 3.4pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+0.8%
Q2 2024
+6.5%
Q3 2024
-1.4%
Q4 2024
-6.2%
Q1 2025
+7.2%
Q2 2025
+6.7%
Q3 2025
+13.1%
Q4 2025
+10.9%
Q1 2026
+33.9%
Sector allocation
Healthcare 96%
Technology 4%
Long book by quarter
What does Crestline Management, own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 3 | $46.3M | SEC ↗ | |
| Q1 2026 | 13F-HR/ARESTATEMENT | May 15, 2026 | 3 | $46.3M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 3 | $53.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 3 | $58.1M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 3 | $62.6M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 3 | $63.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 705 | $3.01B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 514 | $1.92B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 159 | $1.28B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 157 | $1.13B | canonical | SEC ↗ |